RT Journal Article
SR Electronic
T1 Comparison of Efficacy of Adjuvant MEC (Methotrexate, Epirubicin and Cisplatin) and GC (Gemcitabine and Cisplatin) in Advanced Upper Tract Urothelial Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1875
OP 1883
VO 37
IS 4
A1 SHENG-CHUN HUNG
A1 SHIAN-SHIANG WANG
A1 CHUN-KUANG YANG
A1 JIAN-RI LI
A1 CHEN-LI CHENG
A1 YEN-CHUAN OU
A1 HAO-CHUNG HO
A1 KUN-YUAN CHIU
A1 CHUAN-SHU CHEN
YR 2017
UL http://ar.iiarjournals.org/content/37/4/1875.abstract
AB Aim: To evaluate the efficacy of methotrexate, epirubicin and cisplatin (MEC) or gemcitabine and cisplatin (GC) as adjuvant chemotherapy in advanced upper tract urothelium carcinoma (UTUC). Patients and Methods: From 2002 January to 2008 December, a total of 70 patients with advanced UTUC received radical nephroureterctomy at our Institute with MEC and GC as adjuvant chemotherapy. Disease-free survival (DFS), cancer-specific survival (CSS) and overall survival (OS) among the two groups were evaluated. Results: The MEC (n=30) and GC group (n=40) were compared and showed no significant differences in DFS (p=0.859), CSS (p=0.722) and OS (p=0.691). Positive lymph nodes, preoperative creatinine >1.5, old age, a high ECOG state and low BMI are all the independent risk factors of poor prognosis in advanced UTUC. Conclusion: In patients with UTUC, MEC has a non-inferior efficacy to GC in consideration of cancer recurrence, cancer-specific survival and overall survival.